Finance / Stocks

Pfizer (PFE) Stock: Is It a Strong Buy in 2026?

Pfizer (PFE) has shown resilience in early 2026, driven by promising cancer drug performance and strategic shifts in its GLP-1 program, sparking debate among investors.

Mar 31, 2026 15:01 Prediction: Buying Pfizer Stock Today Could Set You Up for Life

Pfizer (PFE) Stock: Is It a Strong Buy in 2026?

Image via Yahoo Finance

TOPIC pfe stock

Health and Science / Pharmaceuticals

Pfizer Beats Q4 2026 Earnings Estimates Despite Covid Product Decline

Pfizer (PFE) has released its Q4 2026 earnings, surpassing expectations despite a decrease in demand for its COVID-19 products. The company reaffirmed its financial outlook for 2026, emphasizing its long-term investments and cost-saving ini...

Feb 03, 2026 13:02 Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Finance / Earnings

Pfizer Beats Earnings Estimates Amid Covid Product Decline

Pfizer (PFE) has reported better-than-expected fourth-quarter earnings for 2026, navigating a decline in demand for its COVID-19 products through robust sales of established drugs and strategic investments in its pipeline. The pharmaceutica...

Feb 03, 2026 12:32 Pfizer Beats Sales Estimates on Demand for Older Drugs

Finance / Investing

Pfizer (PFE) Stock: Investor Analysis and 2026 Outlook

Pfizer Inc. (PFE) has seen significant activity from institutional investors and analysts recently. This article summarizes key transactions, dividend announcements, and the overall outlook for Pfizer stock in 2026.

Feb 02, 2026 15:32 Jones Financial Companies Lllp Has $78.84 Million Position in Pfizer Inc. $PFE

Finance / Stocks

Pfizer Stock: Bargain or Value Trap?

Pfizer (PFE) presents a compelling case for value investors, trading at a low valuation with a high dividend yield. However, concerns about upcoming patent expirations and revenue decline leave investors wondering: Is Pfizer an undervalued...

Jan 26, 2026 16:01 Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?

Finance / Stocks

JNJ vs. PFE Stock: A Comparative Analysis for Investors

Johnson & Johnson (JNJ) and Pfizer (PFE) are two pharmaceutical giants, but their stock performance has diverged significantly. JNJ has surged nearly 45% this year, while PFE has declined by 6%. This article examines the reasons behind this...

Nov 28, 2025 15:32 Which Is A Better Pick: Johnson & Johnson or Pfizer Stock?

Finance / Stocks

Pfizer's Stock: Navigating Challenges and Opportunities

Pfizer (NYSE: PFE) has faced headwinds with declining revenue and profits, leading to a drop in its stock value. However, recent developments, including strategic acquisitions and deals with the U.S. government, offer potential for a turnar...

Oct 06, 2025 13:02 Can Pfizer's Stock Break This Disappointing Streak?

Health / Policy

TrumpRx: Promises and Realities of Lowering Drug Costs

The Trump administration launched TrumpRx, aiming to lower prescription drug costs, but its impact remains uncertain compared to existing solutions like the Inflation Reduction Act.

Oct 06, 2025 12:01 The biggest questions about 'TrumpRx,' the president's plan to reduce drug costs

Health / Weight Loss

Pfizer's Obesity Drug Shows Promise with 14.1% Weight Loss in Trial

Pfizer's $4.9 billion investment in Metsera is showing early promise. A Phase IIb trial of their obesity drug, MET-097i, has demonstrated a significant 14.1% weight loss in patients. This development positions Pfizer to be a strong contende...

Sep 30, 2025 15:33 Pfizer Just Reminded Investors Why You Should Never Count Its Stock Out

Finance / Stocks

Pfizer's Dividend: Is It a Safe Bet?

Pfizer's high dividend yield has attracted income investors, but patent expirations and pipeline uncertainties raise concerns about its long-term sustainability.

Sep 02, 2025 14:32 Pfizer's 7% Dividend: Income Gem or Value Trap?

Finance / Company News

Pfizer's Oncology Division Drives Growth Amidst Market Fluctuations

Pfizer (PFE) is navigating a complex market landscape. While some analysts urge caution due to potential overvaluation after a recent 'dead cat bounce', the company's oncology division is demonstrating robust growth, driven by key drugs and...

Aug 25, 2025 11:01 Pfizer: Don't Be Fooled By The Dead Cat Bounce (NYSE:PFE)

Finance / Earnings

Pfizer (PFE) Earnings: A Mixed Outlook Ahead of Report

Pfizer (PFE) is set to report earnings tomorrow, and analysts are keenly watching to see if the pharmaceutical giant can meet expectations amidst a complex market environment. This report arrives with mixed signals from previous performance...

Aug 05, 2025 10:36 Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason.

Finance / Earnings

Pfizer Q1 Earnings Preview: Analysts Sound Caution

Analysts are approaching Pfizer's Q1 2025 earnings report with caution, citing patent expirations and competitive pressures. However, growth in non-COVID-related products offers a glimmer of optimism. The report is due on April 29th.

Apr 29, 2025 11:03 Pfizer Reports Earnings as Stock Sits in Doldrums